FDA: No major safety concerns with compounded hydroxyprogesterone caproate
July 10th 2012FDA recently released the results of an analysis of a limited number of samples of hydroxyprogesterone caproate active pharmaceutical ingredients and compounded hydroxyprogesterone caproate, finding no major safety concerns.
Vitamin D plus calcium and mortality among elderly
July 5th 2012Vitamin D plus calcium supplementation consistently reduced mortality among elderly patients compared with vitamin D supplementation alone, according to a study published online May 17 in the Journal of Clinical Endocrinology and Metabolism.
Study: Older patients often ignore Rx warning labels
July 5th 2012Brightly colored prescription warning labels applied by pharmacies fail to adequately capture the attention of older patients, suggesting that current labeling standards should be reconsidered to make them more effective, according to a study published online June 14 in PLoS ONE.
McKesson's medication adherence network
July 3rd 2012At their recent ideaShare event, McKesson highlighted its Sponsored Clinical Services Network for hundreds of independent retail pharmacy owners and community pharmacists who are focused on increasing their role in healthcare delivery, improving patient outcomes, and finding new reimbursement avenues, the company said in a release.
FDA approves generic version of acne treatment
July 3rd 2012FDA has approved Perrigo Company’s abbreviated new drug application for a generic version of clindamycin phosphate and benzoyl peroxide 1.2%/5% gel (Duac Gel, Stiefel Laboratories), the company recently announced in a statement. The gel is indicated for the topical treatment of inflammatory acne vulgaris.
Combination therapy for youth with type 2 diabetes
June 28th 2012A combination of 2 diabetes drugs, metformin and rosiglitazone (Avandia, GlaxoSmithKline), was more effective in treating youth with recent-onset type 2 diabetes than metformin alone, a study funded by the National Institutes of Health has found.
FDA approves first weight-loss treatment in over a decade
June 28th 2012FDA has approved lorcaserin (Belviq, Arena Pharmaceuticals and Eisai) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients who are overweight or obese and have at least one weight-related comorbid condition. It is the first prescription weight-loss treatment approved by FDA in 13 years.
State Boards of Pharmacy -- watchdogs or lapdogs?
June 28th 2012When most of our pharmacy practice acts were first promulgated, our profession consisted mainly of independently operated community pharmacies, and the pharmacists who ran them volunteered to operate the state Boards of Pharmacy. Things are different now.
Certain EDCs linked to allergy risk in kids
June 25th 2012Urinary levels of the antimicrobial endocrine-disrupting compounds triclosan and parabens were significantly associated with allergic sensitization in children ages 6 to 18 years, according to the results of a study published online June 18 in the Journal of Allergy and Clinical Immunology.
Humana, Novo Nordisk partner for diabetes care
June 25th 2012Humana Inc. and Novo Nordisk have announced a one-year partnership aimed at identifying ways to improve the care and treatment of patients with diabetes. The companies say they will bring together researchers to study the treatment and progression of the disease in an effort to further enhance the health and well-being of people with diabetes.
Two pilot projects to test PDMPs
June 25th 2012Healthcare providers and pharmacists will be able to identify and intervene in cases of potential prescription drug abuse through a new pilot program launched recently by the Department of Health and Human Services (HHS) Office of the National Coordinator for Health Information Technology, according to an HHS statement.
FDA issues complete response letter for ACS indication for rivaroxaban
June 22nd 2012FDA issued a complete response letter regarding a supplemental New Drug Application for rivaroxaban (Xarelto, Janssen Research & Development) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome.
Walgreens acquires 45% share of Alliance Boots, creating global-pharmacy-led, health enterprise
June 19th 2012Walgreens announced today that it has entered into a strategic transaction with Alliance Boots GmbH, creating a global pharmacy retail and wholesale business with more than 11,000 retail stores in 12 countries and more than 370 distribution centers delivering to more than 170,000 pharmacies, doctors, health centers, and hospitals in 21 countries.